Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease entities : Mesoblast limited save search
United States Food & Drug Administration Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease
Published: 2024-03-26 (Crawled : 07:00) - biospace.com/
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Published: 2024-03-26 (Crawled : 03:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 23.18%
H: 0.0%
C: 0.0%
drug disease children food trial submission
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Published: 2024-02-15 (Crawled : 01:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 1.04%
H: 5.13%
C: 4.87%
revascor drug disease children food designation heart grants
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Published: 2024-01-18 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 10.47%
H: 2.63%
C: 1.05%
revascor rare drug disease children food designation heart grants
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Published: 2023-11-26 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 2.26%
H: 2.94%
C: 0.74%
rare drug disease treatment heart
Atherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsight
Published: 2023-09-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.69%
H: 0.0%
C: 0.0%
NVO | $122.75 -1.43% 0.0% 2.8M
|
Health Technology
|
| O: -0.51%
H: 0.62%
C: 0.42%
BSX | $67.42 -0.8% -0.53% 5.9M
|
Health Technology
|
| O: -0.09%
H: 0.72%
C: -1.29%
SLN | $21.98 1.95% 1.91% 120K
|
Health Technology
|
| O: -1.3%
H: 2.44%
C: -1.42%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 3.25%
H: 1.57%
C: -3.15%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: 0.99%
H: 2.09%
C: 0.83%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 1.0%
H: 0.69%
C: -1.01%
disease cardiovascular growth market
Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Published: 2023-08-04 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -63.91%
H: 14.58%
C: 13.89%
drug disease children license food application response
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023
Published: 2023-03-08 (Crawled : 01:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 10.89%
H: 18.45%
C: 11.61%
fda disease children application resubmission license response
Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Published: 2023-01-31 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 9.09%
H: 3.61%
C: -0.28%
fda disease children application license
Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Published: 2022-11-22 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 3.08%
H: 0.15%
C: -0.3%
disease children
Single Dose of Mesoblast’s Allogeneic Cell Therapy Provides Durable Pain Reduction for at Least Three Years in Patients With Degenerative Disc Disease
Published: 2022-01-12 (Crawled : 03:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 6.4%
H: 0.0%
C: -3.21%
disease
Mesoblast Provides Update Following Meeting With FDA’s OTAT on Remestemcel-L for Children With Acute Graft Versus Host Disease
Published: 2021-12-30 (Crawled : 01:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 0.0%
H: 2.3%
C: -0.21%
fda disease cel children
Heart Disease Therapies Pack a Punch with Promising Study Results
Published: 2021-11-16 (Crawled : 17:00) - biospace.com/
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -1.63%
H: 0.0%
C: 0.0%
disease heart disease heart results therapy
Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases
Published: 2021-07-19 (Crawled : 01:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -2.51%
H: 0.83%
C: -0.86%
covid disease gene therapies trial gene therapy therapy
Mesoblast Presents Respiratory Function Results of COVID-19 ARDS Trial at Pulmonary Disease Conference
Published: 2021-07-16 (Crawled : 01:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -2.97%
H: 0.0%
C: 0.0%
covid disease results respiratory trial conference covid-19
Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
Published: 2021-06-30 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 4.28%
H: 0.0%
C: -2.05%
disease
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
Published: 2021-05-25 (Crawled : 12:00) - biospace.com/
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -1.34%
disease respiratory research
Worldwide Cell Therapy Industry to 2027 - Increasing Prevalence of Chronic Diseases is Driving the Market
Published: 2021-04-01 (Crawled : 13:00) - prnewswire.com
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 0.08%
H: 0.25%
C: -0.4%
VCEL | $43.86 -5.19% -5.47% 430K
|
Health Technology
|
| O: 1.89%
H: 0.25%
C: -6.01%
NUVA | $39.75 -2.24% -2.29% 0
|
Health Technology
|
| O: -0.46%
H: 0.28%
C: -0.89%
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 0.6%
H: 2.76%
C: -0.12%
disease therapy
Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease
Published: 2021-02-10 (Crawled : 00:00) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 15.64%
H: 2.01%
C: -4.45%
disease opioid injection results phase 3 trial
Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease
Published: 2020-12-07 (Crawled : 11:01) - globenewswire.com
MESO | $5.14 2.6% 2.53% 270K
|
Health Technology
|
| O: 3.29%
H: 0.42%
C: -0.54%
disease biomarkers
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.